Status:
ACTIVE_NOT_RECRUITING
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborating Sponsors:
Massachusetts Institute of Technology
TriNetX, LLC
Conditions:
Pancreatic Adenocarcinoma
Predictive Cancer Model
Eligibility:
All Genders
40-100 years
Brief Summary
The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the gene...
Detailed Description
To prospectively validate, implement in real-time, and assess performance of an EHR- based PDAC risk-prediction model. To test the hypothesis that our model will reliably predict PDAC in a real-time c...
Eligibility Criteria
Inclusion
- Male and females age \>= 40 years from 44 US HCOs from the TriNetX platform
- at least 2 clinical encounters to the HCO, within the last year, before the study start date
Exclusion
- Personal history of PDAC or current PDAC
- Age below 40
- Notes on sampling method: no sampling was performed. All eligible individuals are included in this study.
Key Trial Info
Start Date :
July 17 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2026
Estimated Enrollment :
6134060 Patients enrolled
Trial Details
Trial ID
NCT05973331
Start Date
July 17 2023
End Date
September 1 2026
Last Update
November 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115